← Leaderboards
Marc Robillard
University Of Missouri-Columbia
$289,897
Attributed
$579,794
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $214.7K · FY2013–15$250K$187.5K$125K$62.5K$0
'13
'14
'15
Funding mix
By agency
NIH$579,794 · 1
By mechanism
R21$579,794 · 1
Top collaborators
- Thomas P Quinn3 shared
Most similar at University Of Missouri-Columbia
Same institution · by research overlap
- Kattesh V Katti$3,115,330
- Jered C Garrison$6,180,863
Others in their field
Top investigators on “Adverse Effects”
- James Dennis Neaton · Northwestern University$203,539,316
- John M Lachin · George Washington University$139,991,329
- Elizabeth A Thom · George Washington University$126,101,581
- David M Nathan · Massachusetts Institute Of Technology$120,651,895
- Constance Ann Benson · University Of California, San Diego$114,806,215
- Wafaa M. El-Sadr · Columbia University Health Sciences$102,102,044
Research focus
Adverse EffectsAcidsAlkenesAntibodiesAffinityAntibody TherapyAntigensBacteriophagesBaseBinding (Molecular Function)BiodistributionAntibody ConjugateBispecific AntibodiesBloodCancer ModelCancer Radiation TherapyCancer RadioimmunotherapyCancer TherapyCarbohydratesCell LineChelating AgentsChemistryClinically RelevantColon Carcinoma
Grant awards (3)
In vivo metal-free cycloaddition chemistry driven pretargeted cancer radiotherapy$214,667
R21 · FY2015 · CA
In vivo metal-free cycloaddition chemistry driven pretargeted cancer radiotherapy$190,493
R21 · FY2014 · CA
In vivo metal-free cycloaddition chemistry driven pretargeted cancer radiotherapy$174,634
R21 · FY2013 · CA